Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + semustine + vincristine
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents: - **Fluorouracil (5-FU):** An antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and repair by mimicking uracil and being incorporated into RNA and DNA. - **Semustine (MeCCNU):** A nitrosourea alkylating agent that crosslinks DNA, leading to inhibition of DNA replication and cell death. - **Vincristine:** A vinca alkaloid that binds to tubulin, inhibiting microtubule formation during mitosis, resulting in cell cycle arrest at metaphase. This combination has been studied primarily for the treatment of advanced or metastatic colorectal cancer. It is not a branded regimen but rather an investigational or historical protocol used in clinical trials[1][2][8]. The mechanism involves multi-pronged disruption of cancer cell proliferation through interference with nucleic acid synthesis (fluorouracil), direct DNA damage (semustine), and mitotic arrest (vincristine).
- Other names
- 5-fluorouracil + semustine + vincristine5-FU + MeCCNU + VCR
02
Targets
MicrotubuleDNATS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + semustine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + semustine + vincristine.